Revenue Breakdown
Composition ()
No data
Revenue Streams
Merck & Co Inc (MRK) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Oncology-Keytruda, accounting for 50.3% of total sales, equivalent to $7.96B. Other significant revenue streams include Vaccines -Gardasil/Gardasil and Animal Health-Livestock. Understanding this composition is critical for investors evaluating how MRK navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Merck & Co Inc maintains a gross margin of 78.10%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 39.70%, while the net margin is 33.50%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MRK converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, MRK competes directly with industry leaders such as NVS and AZN. With a market capitalization of $266.87B, it holds a significant position in the sector. When comparing efficiency, MRK's gross margin of 78.10% stands against NVS's 75.38% and AZN's 81.17%. Such benchmarking helps identify whether Merck & Co Inc is trading at a premium or discount relative to its financial performance.
